查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
人體疫苗的全球市場
市場調查報告書
商品編碼
1198931

人體疫苗的全球市場

Human Vaccines
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 262 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球人體疫苗的市場規模在分析期間(2022年～2030年)時預計將以7.5％的年複合成長率增長，從2022年的402億美元，2030年達到714億美元。

本報告所分析的市場區隔之一的肌肉·皮下注射，在分析期間中預計將以8％的年率增長，並達到587億美元。

本報告提供全球人體疫苗市場的相關調查，提供Covid-19影響，趨勢和成長要素，各地區的市場分析，競爭情形，主要企業的簡介等資訊。

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場的展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他的歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他的亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他的南美
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他的中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-1176

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Human Vaccines Market to Reach $71.4 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Human Vaccines estimated at US$40.2 Billion in the year 2022, is projected to reach a revised size of US$71.4 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2022-2030. Intramuscular & Subcutaneous, one of the segments analyzed in the report, is projected to record a 8% CAGR and reach US$58.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Oral segment is readjusted to a revised 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $10.9 Billion, While China is Forecast to Grow at 12.1% CAGR

The Human Vaccines market in the U.S. is estimated at US$10.9 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.8 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 7.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$9.9 Billion by the year 2030.

Select Competitors (Total 16 Featured):

  • ALK - Abello A/S
  • Altimmune, Inc.
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech
  • BiondVax Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Janssen Pharmaceuticals Inc.
  • MedImmune
  • Mitsubishi Tanabe Pharma
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • SK BioScience
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Human Vaccines: A Prelude
    • Recent Market Activity
    • Competitive Scenario
    • Vaccine Pricing: A Review
    • Human Vaccines - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • ALK - Abello A/S (Denmark)
    • Altimmune, Inc. (USA)
    • Astellas Pharma Inc. (Tokyo)
    • Bavarian Nordic (Denmark)
    • BiondVax Pharmaceuticals Ltd. (Israel)
    • Bharat Biotech (India)
    • GlaxoSmithKline Plc. (UK)
    • Hualan Biological Engineering Inc. (China)
    • Janssen Pharmaceuticals, Inc. (USA)
    • MedImmune (USA)
    • Merck Sharp & Dohme Corp., (USA)
    • Mitsubishi Tanabe Pharma Corporate (Japan)
    • Pfizer, Inc. (USA)
    • Sanofi Pasteur SA (France)
    • Serum Institute of India Pvt. Ltd. (India)
    • Seqirus (UK)
    • SK BioScience (Korea)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Zydus Cadila (India)
  • 3. MARKET TRENDS & DRIVERS
    • Combination Vaccines Market Driven by Fast Expanding Pediatric Population
    • List of Combination Vaccines in the US: 2018
    • Gardasil 9 Offers Protection against HPV for Expanded Age Group
    • Increasing Demand for Recombinant Vaccines
    • Global Cholera Vaccines Market
    • Further Clinical Trials Needed for an Effective Zika Vaccine
    • Merck's rVSV-ZEBOV Ebola Vaccine used for Ring Vaccination in Congo
    • Rising Dengue Cases Drive Vaccines Demand
    • Sanofi's Dengue Vaccine First-to-Market
    • EMA Recommends Approval of Dengue Vaccine
    • Vaccine for AIDS
    • Staggering Global Statistics of AIDS - Opportunity Indicator
    • Toxoid Vaccines Market
    • H1N1 Vaccines Market
    • HSV Vaccine on the Horizon
    • Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
    • BCG Vaccines
    • Key TB Vaccine Candidates in the Pipeline: 2018
    • New Vaccine for Herpes Zoster or Shingles
    • Two-dose Hepatitis B Vaccine for Adults
    • Global Rotavirus Vaccines Market
    • Typhoid Vaccines Market
    • Measles Vaccines Market
    • DNA Vaccines: Engineering Growth
    • Mobile Money Encourages Parents for Vaccinating Children
    • Noninjectable Vaccines: Gain without Pain
    • Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
    • Novel Technologies Ensure Timely Vaccine Delivery for Patients in Remote Locations
    • Smart mRNA Vaccines
    • Growing Pricing Pressure - A Major Market Deterrent
    • Safety Issues Come to the Fore
    • Novel Vaccination Guidelines Mitigate Risks Associated with Developing Shoulder Injuries
    • BioWarfare: Threat Perception and Preparedness
    • Overview of Potential Bio-Terrorist Agents
    • Smallpox (Variola Major)
    • Anthrax (Bacillus Anthracis)
    • Plague (Yersinia Pestis)
    • Botulism (Clostridium Botulinum)
    • Tularemia (Francisella Tularensis)
    • Tackling Cold Chain Issues
    • Trade Statistics
    • Growing Incidence of Infectious Diseases Drives the Global Human Vaccines Market
    • Total Number of Infectious Disease Covered under Vaccination
    • Conjugate Vaccines Rule in Human Vaccines Market
    • Pneumococcal Vaccines - A Major Segment
    • Vaccine Pipeline by Major Companies
    • GSK Vaccine Pipeline
    • Merck Vaccines Pipeline
    • Pfizer Vaccines Pipeline
    • Sanofi Vaccines Portfolio
    • Emergent BioSolutions Inc. - Vaccine Pipeline
    • Astellas Pharma - Vaccines
    • Pediatric Vaccines Dominate the Human Vaccines Market
    • Select Pediatric Vaccines
    • Adults Vaccine Market to Witness Rapid Growth, Driven by Government Initiatives
    • Select Adult Vaccines
    • Developed Markets Dominate, Emerging Regions to Exhibit the Fastest Growth
    • Pneumococcal Vaccines Market Set to Witness Rapid Growth
    • Influenza Vaccines Market: A High Growth Segment
    • Cancer Vaccines Market Offers Potential Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Intramuscular & Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Inactivated & Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Human Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • JAPAN
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • CHINA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: China 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • EUROPE
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • FRANCE
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: France 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • GERMANY
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • INDIA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: India 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: India 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030
  • AFRICA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2023 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2023 & 2030

IV. COMPETITION